1h Free Analyst Time
The herpes zoster therapeutics market is forecasted to grow by USD 5.06 billion during 2023-2028, accelerating at a CAGR of 13.7% during the forecast period. The report on the herpes zoster therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased incidence of herpes zoster, rising geriatric population, and favorable reimbursement policies for medications, including vaccines.
The herpes zoster therapeutics market is segmented as below:
By Product
- Vaccination
- Drug therapy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the herpes zoster therapeutics market covers the following areas:
- Herpes Zoster Therapeutics Market sizing
- Herpes Zoster Therapeutics Market forecast
- Herpes Zoster Therapeutics Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Customer Landscape
10 Geographic Landscape
11 Drivers, Challenges, and Opportunity/Restraints
12 Competitive Landscape
13 Competitive Analysis
14 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global herpes zoster therapeutics market: Abbott Laboratories, Bausch Health Companies Inc., Cipla Inc., East India Pharmaceutical Works Ltd., East West Pharma India Pvt. Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., FDC Ltd., GeneOne Life Science Inc., GlaxoSmithKline Plc, Ikon Remedies Pvt. Ltd., Leeford Healthcare Ltd., Maruho Co. Ltd., Merck and Co. Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is emerging innovative vaccines for disease management."
According to the report, one of the major drivers for this market is the increased incidence of herpes zoster.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Bausch Health Companies Inc.
- Cipla Inc.
- East India Pharmaceutical Works Ltd.
- East West Pharma India Pvt. Ltd.
- Eli Lilly and Co.
- Emcure Pharmaceuticals Ltd.
- FDC Ltd.
- GeneOne Life Science Inc.
- GlaxoSmithKline Plc
- Ikon Remedies Pvt. Ltd.
- Leeford Healthcare Ltd.
- Maruho Co. Ltd.
- Merck and Co. Inc.
- Novartis AG
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Lifesciences Ltd.
